BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tasigna nilotinib: Phase III data

The open-label, international Phase III ENESTcmr trial in 207 patients showed that a non-significantly greater proportion of patients who switched to Tasigna achieved a confirmed CMR, the primary endpoint, vs. patients who continued on Gleevec imatinib at 12 months (13% vs. 6%, p=0.108). A confirmed CMR was defined as undetectable BCR-ABL levels in 2 consecutive samples. Samples with any detectable...

Read the full 290 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >